A target validation study of Fimepinostat in children and adolescents with newly diagnosed diffuse intrinsic pontine glioma (DIPG), recurrent medulloblastoma, or recurrent high-grade glioma (HGG).

Switzerland, United States (ICTRP)

ID di studio ICTRP
NCT03893487 (ICTRP)

Titolo ufficiale (approvato dal comitato etico)
A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG) (BASEC)

Titolo accademico
A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG) (ICTRP)

Titolo pubblico
Fimepinostat in Treating Brain Tumors in Children and Young Adults (ICTRP)

Malattie studiate
Diffuse Intrinsic Pontine GliomaRecurrent Anaplastic AstrocytomaRecurrent GlioblastomaRecurrent Malignant GliomaRecurrent Medulloblastoma (ICTRP)

Intervento studiato
Drug: FimepinostatProcedure: Therapeutic Conventional Surgery (ICTRP)

Tipo di studio
Interventional (ICTRP)

Disegno dello studio
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). (ICTRP)

Criteri di inclusione/esclusione
Inclusion Criteria:

- Patients must have one of the following histologically confirmed diagnoses
(histologic confirmation from initial diagnosis acceptable, as appropriate):

- Stratum A: Newly diagnosed diffuse intrinsic pontine glioma (WHO grade II-IV) -
this stratum does not require tissue confirmation at time of enrollment, but
diagnostic confirmation will be required to continue on study after biopsy.
Patients with newly diagnosed DIPG will be eligible to enroll before or after
standard of care radiation, but must be eligible for a biopsy. Newly diagnosed
DIPG stratum should not have received prior therapy before the initiation of
fimepinostat, with the exception of those patients who received temozolomide
during radiation therapy or who previously received radiation as per standard
of care and have not yet undergone a biopsy. All patients who have received
therapy other than radiation and temozolomide should be discussed with study
chair(s) prior to enrollment. Patients enrolling after standard of care
radiation must be enrolled within 14 weeks of completion of radiotherapy.

- Stratum B: Recurrent medulloblastoma (WHO grade IV), any molecular subtype

- Stratum C: Recurrent high-grade glioma (HGG), including anaplastic astrocytoma
(WHO grade III) and glioblastoma (WHO grade IV)

- Stratum B & C: Patients in the recurrent medulloblastoma or recurrent HGG
arm can have locally recurrent or disseminated disease, provided
resection/biopsy would still be clinically indicated. Disseminated disease
can be diagnosed by imaging or Cerebrospinal fluid (CSF) cytology.
Recurrent DIPG will be eligible for stratum C however, eligibility
requires biopsy/resection is feasible in a region of tumor outside of the
pons (i.e. cerebellar extension or new metastatic site). These patients
should be discussed with study chair(s) prior to enrollment

- Patients must be able to swallow intact fimepinostat capsules or mini-tabs without
chewing or crushing

- Patients must have body surface area (BSA) >= 0.5 m^2

- Patients must undergo tumor tissue collection as part of their standard of care

- Minimum possible tissue collected must be equivalent to about 4-6 stereotactic
core biopsies

- Prior Therapy: Patients in the medulloblastoma and HGG strata will be allowed to
have undergone prior therapy including surgery, chemotherapy, and radiation therapy.
Patients in the newly diagnosed DIPG stratum should not have received prior therapy
before the initiation of fimepinostat, with the exception of those patients who
received temozolomide during radiation therapy or who previously received radiation
as per standard of care and have not yet undergone a biopsy. All patients who have
received therapy other than radiation and temozolomide should be discussed with
study chair(s) prior to enrollment. Patients must have fully recovered from acute
side effects related to previous anti-cancer therapies. Patients undergoing
radiation during protocol therapy will not be permitted to receive other concomitant
agents with radiation and pending initiation of maintenance with fimepinostat

- Myelosuppressive chemotherapy: At least 21 days after last dose of
myelosuppressive chemotherapy (42 days if prior nitrosourea)

- Hematopoietic growth factors: At least 14 days after last dose of a long-acting
growth factor or 7 days after short-acting growth factor or beyond time during
which adverse events are known to occur

- Biologic (anti-neoplastic agent): At least 7 days after last dose of a biologic
agent or beyond time during which adverse events are known to occur

- Monoclonal antibodies: At least 21 days after last dose of monoclonal antibody

- Radiotherapy:

- At least 2 weeks after local palliative radiotherapy (XRT)

- At least 3 months from craniospinal XRT, or XRT to > 50% pelvis

- Surgery:

- At least 21 days from major surgery (biopsy and central line
placement/removal are not considered major)

- Corticosteroids: Subjects who are receiving dexamethasone must be on a stable or
decreasing dose for at least 7 days prior to enrollment

- Peripheral absolute neutrophil count (ANC) >= 1000/mm^3

- Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving
platelet transfusions for at least 7 days prior to enrollment)

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
milliliters (mL)/minute (min)/1.73 m^2 or

- A serum creatinine based on age/gender as follows:

- Age: Maximum Serum Creatinine (mg/dL)

- 3 to < 6 years: 0.8 (male), 0.8 (female)

- 6 to < 10 years: 1 (male), 1 (female)

- 10 to < 13 years: 1.2 (male), 1.2 (female)

- 13 to < 16 years: 1.5 (male), 1.4 (female)

- >= 16 years: 1.7 (male), 1.4 (female)

- Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN)
for age

- Serum glutamate pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) =< 110
U/L

- Serum albumin >= 2 g/dL

- Neurologic function:

- Subjects with seizure disorder may be enrolled if well controlled

- Gastrointestinal function:

- Diarrhea < grade 2 by Common Terminology Criteria for Adverse Events (CTCAE)
version (v)5.0

- Metabolic function:

- Non-fasting glucose < 125 mg/dL without the use of antihyperglycemic agents

- If non-fasting glucose > 125 mg/dL, a fasting glucose should be done. If
fasting glucose =< 160 mg/dL without the use of antihyperglycemic agents,
patient will meet adequate metabolic function criteria

- Cardiac function: corrected QT (QTc) < 480 msec

- The effects of fimepinostat on the developing human fetus are unknown. For this
reason, women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control abstinence) prior to
study entry, for the duration of study participation and 30 days after completion of
fimepinostat administration. Should a woman become pregnant or suspect she is
pregnant while she or her partner is participating in this study, she should inform
her treating physician immediately

- A legal parent/guardian or patient must be able to understand, and willing to sign,
a written informed consent and assent document, as appropriate

Exclusion Criteria:

- Subjects who have not recovered from acute adverse events due to therapeutic agents
administered more than 4 weeks earlier

- Patients must not have received prior therapy with single-agent or combination
histone deacetylase (HDAC) and Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)
inhibitors

- Subjects who are receiving any other investigational agent

- History of allergic reaction to compounds of similar chemical or biological (ICTRP)

non disponibile

Endpoint primari e secondari
Penetration of fimepinostat across the blood brain barrier (BBB) (ICTRP)

non disponibile

Data di registrazione
non disponibile

Inclusione del primo partecipante
non disponibile

Sponsor secondari
Pediatric Neuro-Oncology Consortium;Cannonball Kids' Cancer Foundation;Curis, Inc. (ICTRP)

Contatti aggiuntivi
Sabine Mueller, MD, PhD, University of California, San Francisco (ICTRP)

ID secondari
NCI-2019-00144, PNOC016, 18086 (ICTRP)

Risultati-Dati individuali dei partecipanti
non disponibile

Ulteriori informazioni sullo studio
https://clinicaltrials.gov/study/NCT03893487 (ICTRP)